Revenue and Income - Total revenue for the three months ended September 30, 2025, was $363.8 million, representing a 16% increase compared to $312.7 million in the same period of 2024[104] - The company reported a net income of $1.1 million for the three months ended September 30, 2025, compared to a net loss of $6.0 million in the same period of 2024[104] - The company’s revenue growth for the nine months ended September 30, 2025, was 13%, compared to 19% for the same period in 2024[104] - Total revenue for the nine months ended September 30, 2025, increased by $116.6 million, or 13%, to $1,042.1 million from $925.5 million in the same period in 2024[117] Adjusted EBITDA - Adjusted EBITDA for the nine months ended September 30, 2025, was $108.9 million, compared to $87.0 million for the same period in 2024, reflecting a growth of 25%[104] - Adjusted EBITDA for the three months ended September 30, 2025, was $40.2 million, compared to $30.7 million for the same period in 2024, reflecting a 31% increase[111] Patient Visits and Clinician Employment - The number of clinicians employed as of September 30, 2025, was 7,996, contributing to the company's capacity to treat patients[90] - The company facilitated 2.3 million visits in the three months ended September 30, 2025, and 6.6 million visits in the nine months ended September 30, 2025[93] - Patient service revenue rose by $51.7 million, primarily due to a net increase of 764 clinicians and a 17% increase in patient visits[116] Center Costs and Expenses - Center costs, excluding depreciation and amortization, increased by $34.9 million, or 16%, to $247.2 million for the three months ended September 30, 2025, driven by a $33.5 million increase in center-based compensation[120] - Center costs, excluding depreciation and amortization, increased by $74.8 million, or 12%, to $707.3 million for the nine months ended September 30, 2025[121] - General and administrative expenses increased by $10.3 million, or 12%, to $95.6 million for the three months ended September 30, 2025, compared to $85.3 million for the same period in 2024[123] - For the nine months ended September 30, 2025, general and administrative expenses rose by $18.0 million, or 7%, to $287.4 million from $269.4 million in 2024[124] Cash Flow and Financial Position - Cash and cash equivalents increased to $203.9 million as of September 30, 2025, from $154.6 million as of December 31, 2024[132] - Net cash provided by operating activities was $88.6 million for the nine months ended September 30, 2025, compared to $44.9 million in 2024[139] - Cash flows used in investing activities amounted to $25.2 million for the nine months ended September 30, 2025, up from $15.3 million in 2024[140] - The company believes existing cash and cash equivalents will be sufficient to fund operating and capital needs for at least the next 12 months[133] Future Growth and Strategy - The company aims to expand its clinician base and has developed a national recruiting model to support this growth[92] - The company plans to open new centers to increase capacity and address patient needs in existing and new markets[100] - The company anticipates continued revenue growth driven by in-house clinician recruiting and new center strategies, as well as increased patient visits through virtual sessions[119] - The company expects general and administrative expenses to continue increasing due to planned investments for growth[125] - The company expects center costs to continue increasing in the short- to medium-term as it invests strategically to expand its business[122] Interest and Depreciation - Depreciation and amortization expense decreased by $1.5 million to $13.6 million for the three months ended September 30, 2025, from $15.1 million in 2024[126] - Interest expense, net decreased by $2.6 million to $2.8 million for the three months ended September 30, 2025, from $5.4 million in 2024[128]

Financial Performance - Q3 2025 revenue reached $363.8 million, a 16% year-over-year increase[10, 12] - Center Margin for Q3 2025 was $116.6 million, representing 32.0% of revenue[10, 12] - Adjusted EBITDA for Q3 2025 was $40.2 million, or 11.1% of revenue[10, 12] Operational Metrics - Total clinicians increased to 7,996, an 11% year-over-year growth, with 288 net clinician additions in Q3[10, 12] - Q3 2025 visit volumes totaled 2.3 million, a 17% year-over-year increase[10] - The company ended Q3 with a cash position of $203.9 million[10] Guidance - The company reaffirmed its FY 2025 revenue guidance midpoint of $1.41 billion - $1.43 billion[20] - The company raised its FY 2025 Center Margin guidance from $441-$465 million to $448-$462 million[20] - The company raised its FY 2025 Adjusted EBITDA guidance from $140-$150 million to $146-$152 million[20]

Core Insights - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.01, and showing improvement from a loss of $0.02 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company achieved revenues of $363.81 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.30% and up from $312.72 million in the same quarter last year [2] - LifeStance Health has outperformed consensus EPS estimates in all four quarters over the past year and has topped revenue estimates three times during the same period [2] Financial Performance - The company's shares have declined approximately 34.7% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $383.44 million, while for the current fiscal year, the estimate is -$0.02 on revenues of $1.42 billion [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - LifeStance Health Group, Inc. reported a record-breaking third quarter for 2025, achieving 17% organic visit growth and positive net income of $1 million, alongside an Adjusted EBITDA of $40 million with 11% margins, indicating strong operational performance and improved productivity [3][4][6]. Financial Highlights - Total revenue for Q3 2025 reached $363.8 million, a 16% increase from $312.7 million in Q3 2024 [4][6]. - Income from operations was $7.4 million, compared to a break-even result in Q3 2024 [4][6]. - Center Margin grew 16% to $116.6 million, representing 32.0% of total revenue [4][6]. - Net income was $1.1 million, a significant turnaround from a net loss of $6.0 million in the previous year [4][6]. - Adjusted EBITDA increased by 31% to $40.2 million, reflecting improved operating leverage [4][6]. Operational Metrics - The clinician base expanded by 11% to approximately 8,000, with a net increase of 288 clinicians in Q3 2025 [5][6]. - Visit volumes increased by 17% to 2.3 million in the third quarter [5][6]. - Cash flow from operations for the nine months ended September 30, 2025, was $88.6 million, including $27.3 million in Q3 [5][6]. 2025 Guidance - The company reiterated its revenue expectations for the full year 2025, projecting between $1.41 billion and $1.43 billion, while raising midpoint expectations for Center Margin to between $448 million and $462 million [12][5]. - Adjusted EBITDA expectations for 2025 were also raised to a range of $146 million to $152 million [12][5]. - For Q4 2025, total revenue is expected to be between $368 million and $388 million, with Center Margin projected at $113 million to $127 million [12].

Financial Performance - Total revenue for Q3 2025 was $363.8 million, a 16% increase from $312.7 million in Q3 2024[3] - Net income for Q3 2025 was $1.1 million, compared to a net loss of $6.0 million in the prior year, representing a 118% improvement[4] - Adjusted EBITDA increased by 31% to $40.2 million, with an Adjusted EBITDA margin of 11.1%[6] - For the full year 2025, the company expects revenue between $1.41 billion and $1.43 billion, with Adjusted EBITDA guidance raised to $146 million to $152 million[12] - Total revenue for the three months ended September 30, 2025, was $363.8 million, a 16.4% increase from $312.7 million in the same period of 2024[21] - Net income for the three months ended September 30, 2025, was $1.1 million, compared to a net loss of $6.0 million in the same period of 2024[21] - Adjusted EBITDA for the nine months ended September 30, 2025, was $108.9 million, a 25.2% increase from $87.0 million in the same period of 2024[26] Operational Metrics - The clinician base grew by 11% to 7,996 clinicians, with a net increase of 288 clinicians in Q3 2025[4] - Visit volumes increased by 17% to 2.3 million in Q3 2025[4] - Center Margin for Q3 2025 was $116.6 million, representing 32.0% of total revenue, a 16% increase year-over-year[5] - Center margin for the three months ended September 30, 2025, was $116.6 million, compared to $100.4 million in the same period of 2024[24] Cash Flow and Debt - Net cash provided by operations was $27.3 million in Q3 2025, contributing to a strong cash position of $203.9 million[4] - Free Cash Flow for Q3 2025 was positive at $17.0 million[4] - Cash flows from operating activities for the nine months ended September 30, 2025, were $88.6 million, compared to $44.9 million in the same period of 2024[23] - Cash and cash equivalents at the end of the period on September 30, 2025, were $203.9 million, up from $102.6 million at the end of September 2024[23] - The company reported a net increase in cash and cash equivalents of $49.3 million for the nine months ended September 30, 2025[23] - The company ended Q3 2025 with net long-term debt of $269.4 million[7] Expenses - Operating expenses for the three months ended September 30, 2025, totaled $356.4 million, up from $312.7 million in the same period of 2024[21] - General and administrative expenses for the three months ended September 30, 2025, were $95.6 million, an increase from $85.3 million in the same period of 2024[21] - Depreciation and amortization for the nine months ended September 30, 2025, was $41.3 million, down from $56.3 million in the same period of 2024[23]

Core Insights - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States [3] - The company will present at the UBS Global Healthcare Conference on November 10, 2025, at 4:15 p.m. Eastern time [1] - The presentation will be led by CEO Dave Bourdon and moderated by Kevin Caliendo [1] Company Overview - LifeStance Health was founded in 2017 and focuses on reimagining mental health care [3] - The company provides both virtual and in-person outpatient mental health services for children, adolescents, and adults [3] - LifeStance employs approximately 7,700 mental health professionals and operates over 550 centers across 33 states [3]

Core Insights - Calm Health has partnered with LifeStance Health to enhance access to mental health care for users of the Calm Health app, allowing for a more streamlined connection to licensed mental health clinicians when higher-acuity treatment is needed [1][3] - The partnership aims to simplify the process for individuals seeking personalized mental health care, enabling them to receive appropriate support based on their unique needs [2][3] Calm Health Overview - Calm Health is an evidence-based mental health app that provides personalized care plans through a brief mental health screening and onboarding questionnaire [2][3] - The app connects users to various levels of support, including in-app resources and referrals to external services like LifeStance Health [2][3] - Currently, Calm Health is available to over 26 million individuals through health plans, providers, and employers [3][4] LifeStance Health Overview - LifeStance Health is one of the largest providers of virtual and in-person outpatient mental health care in the U.S., offering services for a range of mental health conditions [4][5] - The company operates more than 550 centers across 33 states and employs approximately 7,700 mental health professionals [5] - LifeStance accepts most insurance plans, facilitating affordable access to care, with patients typically able to schedule their first appointment within one week [3][4] Industry Context - Approximately one in five U.S. adults experience mental illness annually, yet only half receive the necessary treatment, highlighting the need for improved access to mental health resources [3] - The collaboration between Calm Health and LifeStance is positioned to address this gap by providing streamlined opportunities for patients to engage with care [3]

Core Insights - LifeStance Health Group, Inc. is set to release its third quarter 2025 earnings on November 6, 2025, before market opening [1] - A live earnings conference call will be held on the same day at 8:30 a.m. Eastern Time to discuss the results [2] - The company provides access to a real-time audio webcast of the earnings call on its Investor Relations website [3] Company Overview - Founded in 2017, LifeStance is one of the largest providers of outpatient mental health care in the U.S., offering both virtual and in-person services [4] - The company employs approximately 7,700 mental health professionals and operates over 550 centers across 33 states [4] - LifeStance's mission focuses on improving access to affordable and personalized mental health care for individuals of all ages [4]

Core Insights - The company operates in a crowded but highly fragmented mental health space, positioning itself as a leader in outpatient mental health services [2]. Group 1: Company Differentiation - The company has a significant scale with over 7,500 clinicians and is expected to conduct 8 million to 9 million visits or sessions this year, serving nearly 1 million patients [2]. - The company offers hybrid delivery of services, providing both in-person and virtual options, unlike many newer entrants that are virtual-only [2]. - The company has nearly 600 centers located across 33 states, enhancing its accessibility and service delivery [2].

Company Overview - LifeStance is a leader in the outpatient mental health space, operating in a crowded but highly fragmented market [2] - The company has over 7,500 clinicians and is expected to conduct 8 million to 9 million visits or sessions this year, serving nearly 1 million patients [2] Differentiation Factors - The scale of operations is a key differentiator, with a significant number of clinicians and patient interactions [2] - LifeStance offers hybrid delivery of services, providing both in-person and virtual care, unlike many newer entrants that are virtual-only [2] - The company operates nearly 600 centers across 33 states, enhancing its accessibility and service delivery [2]